HLS Therapeutics Inc.
HLTRF
$2.72
$0.082.96%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 62.79% | 48.22% | 55.84% | 19.12% | 51.76% |
| Total Depreciation and Amortization | 0.78% | 3.28% | 0.53% | 0.05% | -6.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -244.46% | -191.64% | -82.60% | 94.25% | -61.52% |
| Change in Net Operating Assets | -160.05% | 92.00% | 44,900.00% | -37,050.00% | 52.31% |
| Cash from Operations | -37.01% | 79.71% | 103.03% | 64.96% | 82.77% |
| Capital Expenditure | -- | -- | -153.85% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 94.00% | -- | -- | -- | -107.55% |
| Cash from Investing | 94.48% | -1,723.81% | -2,330.77% | 81.40% | -108.20% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 85.92% | -69.55% | -95.67% | -288.69% | -437.82% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 98.08% | -- | -- | -- | -162.78% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 87.04% | -60.45% | -102.26% | 77.19% | -266.86% |
| Foreign Exchange rate Adjustments | -156.95% | -442.86% | 119.61% | -206.67% | 413.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 125.16% | 116.91% | 1,225.00% | 90.82% | -142.69% |